Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Clinical & Experimental Metastasis
Published in: Clinical & Experimental Metastasis 8/2009

01-12-2009 | Research Paper

Metastasis-induction and apoptosis-protection by TWIST in gastric cancer cells

Authors: Mei-yan Feng, Kuan Wang, Hong-tao Song, Hong-wei Yu, Yu Qin, Qing-tao Shi, Jing-shu Geng

Published in: Clinical & Experimental Metastasis | Issue 8/2009

Login to get access

Abstract

TWIST, a basic helix-loop-helix transcription factor, has been recently reported to play an important role in tumorigenesis of human cancer through converting the early stage tumors into invasive malignancies. Upregulation of TWIST is often found in cancer patients, especially those with shorter survival period and poor response to chemotherapy. Here we studied the functions of TWIST on regulating migration rate, apoptosis, and gene expression in gastric cancer cells. TWIST expression is elevated in MGC-803 and HGC-27 cells that exhibit high invasive potential; whereas it is reduced in BGC-823 and SGC-7901 cells that possess relatively low invasive content. To evaluate functional consequences of TWIST induction, we examined the effect of TWIST on cell migration and apoptosis. Overexpression of TWIST in BGC-823 cells resulted in increased migration content and decreased sensitivity to the arsenic oxide-induced cell death. Moreover, small interference RNA-mediated TWIST ablation in MGC-803 and HGC-27 cells showed suppressed migration ability, increased induction of apoptosis in response to arsenic oxide, and elevated cell cycle arrest. Furthermore, we found a negative correlation between the TWIST level and p53 level, probably due to transcriptional regulation. Our results have identified TWIST as a critical regulator of gastric cancer cell proliferation and migration, suggesting a potential therapeutic approach to inhibit the growth and metastasis of gastric cancer through inactivation of TWIST.
Appendix
Available only for authorised users
Literature
1.
2.
O’Rourke MP, Tam PP (2002) Twist functions in mouse development. Int J Dev Biol 46:401–413PubMed
3.
Cai J, Goodman BK, Patel AS, Mulliken JB, Van Maldergem L, Hoganson GE, Paznekas WA, Ben-Neriah Z, Sheffer R, Cunningham ML, Daentl DL, Jabs EW (2003) Increased risk for developmental delay in Saethre-Chotzen syndrome is associated with TWIST deletions: an improved strategy for TWIST mutation screening. Hum Genet 114:68–76CrossRefPubMed
4.
Vesuna F, van Diest P, Chen JH, Raman V (2008) Twist is a transcriptional repressor of E-cadherin gene expression in breast cancer. Biochem Biophys Res Commun 367:235–241CrossRefPubMed
5.
Cheng GZ, Chan J, Wang Q, Zhang W, Sun CD, Wang LH (2007) Twist transcriptionally up-regulates AKT2 in breast cancer cells leading to increased migration, invasion, and resistance to paclitaxel. Cancer Res 67:1979–1987CrossRefPubMed
6.
Pesce S, Benezra R (1993) The loop region of the helix-loop-helix protein Id1 is critical for its dominant negative activity. Mol Cell Biol 13:7874–7880PubMed
7.
Hosono S, Kajiyama H, Terauchi M, Shibata K, Ino K, Nawa A, Kikkawa F (2007) Expression of Twist increases the risk for recurrence and for poor survival in epithelial ovarian carcinoma patients. Br J Cancer 96:314–320CrossRefPubMed
8.
Niu RF, Zhang L, Xi GM, Wei XY, Yang Y, Shi YR, Hao XS (2007) Up-regulation of Twist induces angiogenesis and correlates with metastasis in hepatocellular carcinoma. J Exp Clin Cancer Res 26:385–394PubMed
9.
Ohuchida K, Mizumoto K, Ohhashi S, Yamaguchi H, Konomi H, Nagai E, Yamaguchi K, Tsuneyoshi M, Tanaka M (2007) Twist, a novel oncogene, is upregulated in pancreatic cancer: clinical implication of Twist expression in pancreatic juice. Int J Cancer 120:1634–1640CrossRefPubMed
10.
Shibata K, Kajiyama H, Ino K, Terauchi M, Yamamoto E, Nawa A, Nomura S, Kikkawa F (2008) Twist expression in patients with cervical cancer is associated with poor disease outcome. Ann Oncol 19:81–85CrossRefPubMed
11.
Thiery JP (2002) Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2:442–454CrossRefPubMed
12.
Kang Y, Massague J (2004) Epithelial-mesenchymal transitions: twist in development and metastasis. Cell 118:277–279CrossRefPubMed
13.
Howe LR, Watanabe O, Leonard J, Brown AM (2003) Twist is up-regulated in response to Wnt1 and inhibits mouse mammary cell differentiation. Cancer Res 63:1906–1913PubMed
14.
Maestro R, Dei Tos AP, Hamamori Y, Krasnokutsky S, Sartorelli V, Kedes L, Doglioni C, Beach DH, Hannon GJ (1999) Twist is a potential oncogene that inhibits apoptosis. Genes Dev 13:2207–2217CrossRefPubMed
15.
Zhang X, Wang Q, Ling MT, Wong YC, Leung SC, Wang X (2007) Anti-apoptotic role of TWIST and its association with Akt pathway in mediating taxol resistance in nasopharyngeal carcinoma cells. Int J Cancer 120:1891–1898CrossRefPubMed
16.
Kwok WK, Ling MT, Lee TW, Lau TC, Zhou C, Zhang X, Chua CW, Chan KW, Chan FL, Glackin C, Wong YC, Wang X (2005) Up-regulation of TWIST in prostate cancer and its implication as a therapeutic target. Cancer Res 65:5153–5162CrossRefPubMed
17.
Katoh M (2005) Epithelial-mesenchymal transition in gastric cancer (Review). Int J Oncol 27:1677–1683PubMed
18.
Rosivatz E, Becker I, Specht K, Fricke E, Luber B, Busch R, Hofler H, Becker KF (2002) Differential expression of the epithelial-mesenchymal transition regulators snail, SIP1, and twist in gastric cancer. Am J Pathol 161:1881–1891PubMed
19.
Yan-Qi Z, Xue-Yan G, Shuang H, Yu C, Fu-Lin G, Fei-Hu B, Shi-Ren S, Xu-Feng W, Jie D, Dai-Ming F (2007) Expression and significance of TWIST basic helix-loop-helix protein over-expression in gastric cancer. Pathology 39:470–475CrossRefPubMed
20.
Lin CH, Fu ZM, Liu YL, Yang JL, Xu JF, Chen QS, Chen HM (1984) Investigation of SGC-7901 cell line established from human gastric carcinoma cells. Chin Med J (Engl) 97:831–834
21.
Akagi T, Kimoto T (1976) Human cell line (HGC-27) derived from the metastatic lymph node of gastric cancer. Acta Med Okayama 30:215–219PubMed
22.
Wang K (1983) A in vitro cell line (MGc80–3) of a poorly differentiated mucoid adenocarcinoma of human stomach. Acta Biol Exp Sin 16:257–267
23.
Deng GR, Lu YY, Chen SM, Miao J, Lu GR, Li H, Cai H, Xu XL, E Z, Liu PN (1987) Activated c-Ha-ras oncogene with a guanine to thymine transversion at the twelfth codon in a human stomach cancer cell line. Cancer Res 47:3195–3198PubMed
24.
van Engeland M, Nieland LJ, Ramaekers FC, Schutte B, Reutelingsperger CP (1998) Annexin V-affinity assay: a review on an apoptosis detection system based on phosphatidylserine exposure. Cytometry 31:1–9CrossRefPubMed
25.
Shiota M, Izumi H, Onitsuka T, Miyamoto N, Kashiwagi E, Kidani A, Yokomizo A, Naito S, Kohno K (2008) Twist promotes tumor cell growth through YB-1 expression. Cancer Res 68:98–105CrossRefPubMed
26.
Hjiantoniou E, Anayasa M, Nicolaou P, Bantounas I, Saito M, Iseki S, Uney JB, Phylactou LA (2008) Twist induces reversal of myotube formation. Differentiation 76:182–192CrossRefPubMed
27.
Luo GQ, Li JH, Wen JF, Zhou YH, Hu YB, Zhou JH (2008) Effect and mechanism of the Twist gene on invasion and metastasis of gastric carcinoma cells. World J Gastroenterol 14:2487–2493CrossRefPubMed
28.
Yang Z, Zhang X, Gang H, Li X, Li Z, Wang T, Han J, Luo T, Wen F, Wu X (2007) Up-regulation of gastric cancer cell invasion by Twist is accompanied by N-cadherin and fibronectin expression. Biochem Biophys Res Commun 358:925–930CrossRefPubMed
29.
Horikawa T, Yang J, Kondo S, Yoshizaki T, Joab I, Furukawa M, Pagano JS (2007) Twist and epithelial-mesenchymal transition are induced by the EBV oncoprotein latent membrane protein 1 and are associated with metastatic nasopharyngeal carcinoma. Cancer Res 67:1970–1978CrossRefPubMed
30.
Lo HW, Hsu SC, Xia W, Cao X, Shih JY, Wei Y, Abbruzzese JL, Hortobagyi GN, Hung MC (2007) Epidermal growth factor receptor cooperates with signal transducer and activator of transcription 3 to induce epithelial–mesenchymal transition in cancer cells via up-regulation of TWIST gene expression. Cancer Res 67:9066–9076CrossRefPubMed
31.
Terauchi M, Kajiyama H, Yamashita M, Kato M, Tsukamoto H, Umezu T, Hosono S, Yamamoto E, Shibata K, Ino K, Nawa A, Nagasaka T, Kikkawa F (2007) Possible involvement of TWIST in enhanced peritoneal metastasis of epithelial ovarian carcinoma. Clin Exp Metastasis 24:329–339CrossRefPubMed
32.
Yuen HF, Chan YP, Wong ML, Kwok WK, Chan KK, Lee PY, Srivastava G, Law SY, Wong YC, Wang X, Chan KW (2007) Upregulation of Twist in oesophageal squamous cell carcinoma is associated with neoplastic transformation and distant metastasis. J Clin Pathol 60:510–514CrossRefPubMed
33.
Yuen HF, Chua CW, Chan YP, Wong YC, Wang X, Chan KW (2007) Significance of TWIST and E-cadherin expression in the metastatic progression of prostatic cancer. Histopathology 50:648–658CrossRefPubMed
34.
Zhang Z, Xie D, Li X, Wong YC, Xin D, Guan XY, Chua CW, Leung SC, Na Y, Wang X (2007) Significance of TWIST expression and its association with E-cadherin in bladder cancer. Hum Pathol 38:598–606CrossRefPubMed
35.
Yang Y, Pan X, Lei W, Wang J, Song J (2006) Transforming growth factor-beta1 induces epithelial-to-mesenchymal transition and apoptosis via a cell cycle-dependent mechanism. Oncogene 25:7235–7244CrossRefPubMed
36.
Kwok WK, Ling MT, Yuen HF, Wong YC, Wang X (2007) Role of p14ARF in TWIST-mediated senescence in prostate epithelial cells. Carcinogenesis 28:2467–2475CrossRefPubMed
37.
38.
Pomerantz J, Schreiber-Agus N, Liegeois NJ, Silverman A, Alland L, Chin L, Potes J, Chen K, Orlow I, Lee HW, Cordon-Cardo C, DePinho RA (1998) The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2’s inhibition of p53. Cell 92:713–723CrossRefPubMed
39.
Kimura T, Tomooka M, Yamano N, Murayama K, Matoba S, Umehara H, Kanai Y, Nakano T (2008) AKT signaling promotes derivation of embryonic germ cells from primordial germ cells. Development 135:869–879CrossRefPubMed
40.
Mayo LD, Donner DB (2001) A phosphatidylinositol 3-kinase/Akt pathway promotes translocation of Mdm2 from the cytoplasm to the nucleus. Proc Natl Acad Sci USA 98:11598–11603CrossRefPubMed
Metadata
Title
Metastasis-induction and apoptosis-protection by TWIST in gastric cancer cells
Authors
Mei-yan Feng
Kuan Wang
Hong-tao Song
Hong-wei Yu
Yu Qin
Qing-tao Shi
Jing-shu Geng
Publication date
01-12-2009
Publisher
Springer Netherlands
Published in
Clinical & Experimental Metastasis / Issue 8/2009
Print ISSN: 0262-0898
Electronic ISSN: 1573-7276
DOI
https://doi.org/10.1007/s10585-009-9291-6

Other articles of this Issue 8/2009

Clinical & Experimental Metastasis 8/2009 Go to the issue

Research Paper

Establishment and validation of an in vitro co-culture model to study the interactions between bone and prostate cancer cells

Research Paper

Evaluation of metastatic and angiogenic potentials of human colon carcinoma cells in chick embryo model systems

Research Paper

Strong expression of chemokine receptor CXCR4 by renal cell carcinoma cells correlates with metastasis

Research Paper

Mechanisms and pathways of bone metastasis: challenges and pitfalls of performing molecular research on patient samples

Research Paper

Osteoblasts modulate Ca2+ signaling in bone-metastatic prostate and breast cancer cells

Research Paper

Twist, an independent prognostic marker for predicting distant metastasis and survival rates of esophageal squamous cell carcinoma patients
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits